Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Patellofemoral arthroplasty is cheaper and more effective in the short term than total knee arthroplasty for isolated patellofemoral osteoarthritis: cost-effectiveness analysis based on a randomized trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Thromboembolic and bleeding complications following primary total knee arthroplasty: a Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Ten-year follow-up of stemmed hemiarthroplasty for acute proximal humeral fractures

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Is tranexamic acid use in patients with a hip fracture safe?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Drug-related challenges following primary total hip and knee arthroplasty

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. MRi of the knee compared to specialized radiography for measurements of articular cartilage height in knees with osteoarthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Patient-reported outcomes following interposition arthroplasty of the basal joint of the thumb

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS: The aim is to assess the cost-effectiveness of patellofemoral arthroplasty (PFA) in comparison with total knee arthroplasty (TKA) for the treatment of isolated patellofemoral osteoarthritis (OA) based on prospectively collected data on health outcomes and resource use from a blinded, randomized, clinical trial.

METHODS: A total of 100 patients with isolated patellofemoral osteoarthritis were randomized to receive either PFA or TKA by experienced knee surgeons trained in using both implants. Patients completed patient-reported outcomes including EuroQol five-dimension questionnaire (EQ-5D) and 6-Item Short-Form Health Survey questionnaire (SF-6D) before the procedure. The scores were completed again after six weeks, three, six, and nine months, and again after one- and two-year post-surgery and yearly henceforth. Time-weighted outcome measures were constructed. Cost data were obtained from clinical registrations and patient-reported questionnaires. Incremental gain in health outcomes (quality-adjusted life-years (QALYs)) and incremental costs were compared for the two groups of patients. Net monetary benefit was calculated assuming a threshold value of €10,000, €35,000, and €50,000 per QALY and used to test the statistical uncertainty and central assumptions about outcomes and costs.

RESULTS: The PFA group had an incremental 12 month EQ-5D gain of 0.056 (95% confidence interval (CI) 0.01 to 0.10) and an incremental 12 month cost of minus €328 (95% CI 836 to 180). PFA therefore dominates TKA by providing better and cheaper outcomes than TKA. The net monetary benefit of PFA was €887 (95% CI 324 to 1450) with the €10,000 threshold, and it was consistently positive when different measures of outcomes and different cost assumptions were used.

CONCLUSION: This study provides robust evidence that PFA from a one-year hospital management perspective is cheaper and provides better outcomes than TKA when applied to patients with isolated patellofemoral osteoarthritis and performed by experienced knee surgeons. Cite this article: Bone Joint J 2020;102-B(4):449-457.

Original languageEnglish
JournalThe bone & joint journal
Volume102-B
Issue number4
Pages (from-to)449-457
Number of pages9
ISSN2049-4394
DOIs
Publication statusPublished - Apr 2020

    Research areas

  • Aged, Arthroplasty, Replacement, Knee/economics, Cost-Benefit Analysis, Double-Blind Method, Female, Follow-Up Studies, Health Care Costs/statistics & numerical data, Humans, Knee Prosthesis, Male, Middle Aged, Osteoarthritis, Knee/economics, Patellofemoral Joint/surgery, Quality of Life, Quality-Adjusted Life Years, Surveys and Questionnaires, Treatment Outcome

ID: 61787641